Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
Primary result · Change in arterial TBRResult — go to the resultDifference in Δs −0.02 95% CI −0.19 to 0.15Authors' conclusion
We found that addition of either a TNFi or triple therapy resulted in clinically important improvements in vascular inflammation. However, the addition of a TNFi did not reduce arterial inflammation more than triple therapy.
Study context
- Population
- Patients with active rheumatoid arthritis (RA) despite use of MTX (median age 58 years, 71% women, 57% seropositive, baseline DAS28 4.8 [IQR 4.0, 5.6])115 completed the protocol
- Comparison
- Addition of TNFi vs addition of SSZ and HCQ to MTX for 24 weeks
- Primary endpoint
- Change in arterial inflammation (arterial TBR in carotid arteries and aorta on 18F-FDG-PET/CT), an index of cardiovascular (CV) risk
- Follow-up
- 24 weeks
Methodological detailsactive comparator
- Active comparator
Primary result
Change in arterial TBR
Difference in Δs
−0.02
95% CI −0.19 to 0.15
P = 0.79
Change by group
TNFi
−0.24
SD 0.51
Triple therapy
−0.19
SD 0.51
TNFivs Triple therapy
difference in Δs −0.02 (95% CI −0.19 to 0.15); P = 0.79
As reported in the abstract
Further findings
Association of disease activity change with change in target-to-background ratio (TBR)
- β
- 0.04 (95% CI −0.03 to 0.10)
- Disease activity significantly reduced in both groups
Original publication
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Ann Rheum Dis. Published 30 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →